Hepatitis B Molecular Testing

HBV DNA Test in Kathmandu — Hepatitis B Viral Load, Staging & Monitoring The quantitative molecular test that guides hepatitis B treatment decisions

HBV DNA testing measures hepatitis B viral replication in real time. At Thamel Clinic we use PCR-based quantification for accurate staging, treatment initiation decisions, and long-term monitoring of suppressed patients.

Medically Reviewed Content

Reviewed by: Thamel Clinic Clinical Team (MBBS, MD)

Last medical review: November 8, 2026

Next scheduled review: May 8, 2027

This content follows evidence-based medical guidelines and is regularly updated to reflect current medical practices.

Important Safety Information — Hepatitis B and Viral Load Testing

  • Never stop antiviral medication on your own — sudden withdrawal of hepatitis B treatment can trigger a dangerous immune reactivation flare that may be life-threatening.
  • An undetectable viral load does not mean hepatitis B is cured; the virus can persist in liver cells and require lifelong monitoring.
  • Seek urgent care if you develop severe abdominal pain, yellowing of eyes or skin, confusion, or vomiting blood — these can signal acute liver failure or decompensation.
  • Household contacts of hepatitis B patients should be screened and vaccinated; newborns of infected mothers need prompt prophylaxis within 24 hours of birth.
  • Heavy alcohol use accelerates liver damage in hepatitis B even when viral load is suppressed — limit or avoid alcohol and discuss this with your doctor.

HBV DNA Testing in Nepal

  • High HBV burden — Nepal carries a significant hepatitis B burden, and most infections are acquired in childhood through vertical or horizontal transmission, which is why viral load staging matters so much.
  • Anti-viral access — entecavir and tenofovir are available in Kathmandu pharmacies, but correct treatment decisions require HBV DNA results that many regional clinics cannot provide.
  • Laboratory gaps outside the Valley — quantitative HBV DNA PCR is concentrated in Kathmandu; patients from Pokhara, Butwal and the provinces often travel to the capital for accurate staging.
  • NPHL and referral lab context — Nepal Public Health Laboratory and referral centres offer some molecular testing, but turnaround times and counselling continuity can be limited for private patients.
  • Cost considerations — molecular testing is priced higher than basic serology, so transparent quoting and bundled hepatitis panels help Nepali families plan treatment budgets.

Overview of HBV DNA Testing

HBV DNA testing is a quantitative PCR assay that measures the amount of hepatitis B virus genetic material circulating in the blood, expressed in international units per millilitre (IU/mL). It is the definitive marker of active viral replication and the single most important number in managing chronic hepatitis B. Serology markers such as HBsAg confirm infection, but only viral load reveals whether the virus is multiplying, stable, or suppressed.

The clinical value of HBV DNA lies in its direct link to outcomes. High levels of circulating virus predict faster progression to cirrhosis and liver cancer and identify patients who need treatment. Low or undetectable levels confirm that therapy is working or that the infection is in an inactive carrier state. Current WHO and APASL-style guidance uses DNA thresholds combined with ALT levels and liver imaging to decide when treatment should start.

Patients who benefit most include anyone with chronic hepatitis B in Kathmandu and across Nepal, those being considered for antiviral therapy such as entecavir or tenofovir, people monitoring long-term suppression, and families screening household contacts. Testing is non-invasive, requires only a blood sample, and is completely confidential at our clinic.

This guide explains what HBV DNA measures, when it is ordered, how results are interpreted against ALT and fibrosis markers, what the numbers mean for treatment decisions, and how monitoring works during and after therapy. Note that hepatitis C uses a different viral target — HCV RNA rather than DNA — so the correct molecular assay must be matched to the virus.

What HBV DNA Testing Measures

Hepatitis B is a DNA virus, and its replication produces measurable copies of viral DNA in the bloodstream. The quantitative PCR test amplifies a specific region of the HBV genome and reports the concentration as international units per millilitre. Because the result is expressed in standardised units, results are comparable across laboratories worldwide — a major improvement over older assays that reported copies per millilitre.

The test tells you three things at once: whether replication is active, roughly how aggressively the virus is multiplying, and — most importantly — whether a patient currently meets treatment thresholds. It also serves as the baseline against which all future monitoring is compared.

HBV DNA is different from hepatitis B serology. HBsAg tells you a person is infected, HBeAg tells you they are highly infectious, and antibodies tell you about immune status. DNA quantification is the only routine test that measures how much virus is actively being produced right now.

  • Measured in international units per millilitre (IU/mL) — standardised and comparable between labs.
  • Detects active viral replication, not just past exposure or immunity.
  • Used to decide treatment initiation, not just to confirm infection.
  • Required periodically during antiviral therapy to confirm suppression.
  • Lower limit of detection is typically around 10–20 IU/mL depending on the assay.
  • Non-detectable does not mean cured — the virus can persist in liver cells.

Quantitative, Not Just Positive/Negative

The result is a number — viral load — that trends over time, which makes it far more useful than a simple yes/no result for chronic disease management.

Treatment Trigger

Guidelines use DNA levels together with ALT and fibrosis staging to decide when antiviral therapy should begin and when it can safely be deferred.

Monitoring Tool

During entecavir or tenofovir therapy, DNA is measured every 6–12 months to confirm the virus stays suppressed and to detect rare drug resistance early.

Not a Cure Marker

Even when DNA becomes undetectable, hepatitis B DNA can persist inside liver cells — functional cure is rare, and lifelong monitoring remains necessary.

When HBV DNA Testing Is Ordered

HBV DNA is not ordered on everyone who tests positive for hepatitis B. It is specifically indicated when a clinician needs to know whether viral replication is active enough to warrant treatment. Typically this follows an HBsAg-positive result combined with an elevated ALT, a high HBeAg level, or evidence of liver inflammation on imaging or biopsy.

It is also ordered before starting antiviral therapy to establish a baseline, and repeatedly afterwards to monitor response. Patients who have been on treatment for years need periodic viral load checks because suppression can wane and resistance, though uncommon with modern drugs, still occurs.

Some clinicians also check HBV DNA in pregnancy to assess the risk of mother-to-child transmission, particularly when viral loads are very high — because newborn prophylaxis is most effective when combined with maternal viral suppression. Asking a specialist when the test is genuinely needed prevents unnecessary spending.

  • After a positive HBsAg result when activity is uncertain.
  • Before starting entecavir, tenofovir or similar antivirals — establishes baseline.
  • Every 6–12 months during suppressive therapy to confirm response.
  • When ALT rises unexpectedly during treatment — checks for resistance.
  • During pregnancy with high maternal viral load — assesses transmission risk.
  • When fibrosis staging suggests active disease despite normal ALT.

Baseline Before Treatment

A pre-treatment HBV DNA establishes the starting point. Without it, a later undetectable result cannot prove the therapy caused the suppression.

Pregnancy Planning

High maternal viral load is the strongest predictor of vertical transmission. DNA testing helps decide whether antiviral prophylaxis in late pregnancy is warranted.

Resistance Surveillance

If DNA reappears or climbs while on therapy, resistance testing and a switch of drug may be needed — early detection protects liver function.

Inactive Carrier Review

Patients labelled as inactive carriers still need periodic DNA checks, because some transition to active disease years after diagnosis.

Interpreting HBV DNA Results

HBV DNA results are interpreted in context, never alone. A viral load above roughly 2,000 IU/mL with elevated ALT and signs of inflammation generally indicates a patient who benefits from treatment. Loads in the millions suggest very active replication and high infectivity. Undetectable results confirm suppression but do not mean the virus is gone.

The combined picture matters more than any single number. A patient with DNA of 50,000 IU/mL but normal ALT and no fibrosis may be monitored rather than treated immediately. A patient with lower DNA but clear cirrhosis may need treatment regardless of the exact figure. This is why interpretation by a clinician familiar with hepatology is essential.

False reassurance is the main risk. Patients often assume an undetectable DNA means they are cured and stop attending follow-up or stop medication. In reality, stopping antivirals can trigger dangerous flares — hepatitis B reactivation can be fatal. Our clinic emphasises that viral suppression is managed lifelong care, not a one-off cure.

  • Above ~2,000 IU/mL with elevated ALT — commonly a treatment indication.
  • Very high loads (millions of IU/mL) — highly infectious and faster progression risk.
  • Undetectable — suppression confirmed, but not eradication; monitoring continues.
  • Low-level viremia — may reflect partial control or emerging resistance.
  • Always interpreted with ALT, HBeAg status and fibrosis assessment.
  • Result trends over time are more meaningful than a single reading.

The Number Alone Misleads

A moderate viral load with cirrhosis may need urgent treatment while a higher load without liver damage may be monitored — context decides.

HBeAg Adds Information

Positive HBeAg indicates higher infectivity and active replication; its seroconversion during therapy is a favourable milestone worth tracking.

ALT Correlation

ALT measures liver cell damage. Rising ALT with falling DNA suggests immune clearance; rising ALT with rising DNA suggests treatment failure.

Fibrosis Changes Everything

Liver stiffness or biopsy findings can push a borderline viral load into clear treatment territory, because protecting the liver is the goal.

Treatment Decisions and Ongoing Monitoring

When treatment is indicated, the standard first-line antivirals are entecavir and tenofovir — potent, well-tolerated drugs that suppress HBV DNA to undetectable levels in most patients within a year. Treatment aims for durable viral suppression, normal ALT, and prevention of cirrhosis and liver cancer. It is usually long-term; stopping risks dangerous reactivation.

Monitoring after starting therapy is structured: HBV DNA and ALT are checked regularly in the first year, then spaced out once stable suppression is confirmed. Our clinic coordinates this schedule and reviews results with patients so they understand what each value means for their liver health.

Beyond the numbers, hepatitis B care includes vaccination of household contacts, screening for hepatitis D co-infection where indicated, alcohol counselling, and discussion of liver cancer surveillance once fibrosis is present. Molecular testing is one part of a complete hepatitis B management programme, not a standalone service.

  • Entecavir and tenofovir are the usual first-line suppressive therapies.
  • Goal is undetectable DNA plus normal ALT — durable suppression, not eradication.
  • DNA and ALT checked at intervals; frequency depends on stability.
  • Never stop antivirals without specialist advice — reactivation can be fatal.
  • Household contacts should be tested and vaccinated where indicated.
  • Liver cancer surveillance is added when fibrosis or cirrhosis is present.

Suppression, Not Cure

Modern antivirals control hepatitis B extremely well but rarely eliminate it. Patients should plan for long-term monitoring rather than a finite treatment course.

Drug Choice Matters

Entecavir and tenofovir have different resistance profiles and kidney/bone considerations — selection is personalised to the patient.

Family Protection

Hepatitis B spreads within households, especially to children. Testing and vaccinating contacts is as important as treating the index patient.

Liver Cancer Surveillance

Patients with cirrhosis or significant fibrosis need periodic ultrasound and AFP checks because suppressed hepatitis B still carries cancer risk.

HBV DNA Testing & Related Services in Kathmandu

ServiceWhat It IncludesCost (NPR)
STD/Hepatitis doctor consultationPrivate assessment of results, symptoms and treatment planning.Rs. 450
HBsAg screening (rapid/serology)Detects hepatitis B surface antigen — initial infection screen.Rs. 400–800
HBV DNA quantitative PCRMeasures viral replication in IU/mL — staging and monitoring.Lab rate
Liver function tests (LFT)ALT, AST and related markers — assesses liver damage activity.Rs. 800–1,500
HBeAg / anti-HBe serologyInfectivity and immune status markers used with DNA for decisions.Rs. 600–1,200
Liver stiffness / fibrosis assessmentNon-invasive evaluation of liver scarring where indicated.Lab rate
Antiviral therapy initiationEntecavir or tenofovir prescription with monitoring plan.Per case

Prices are indicative NPR ranges. Final cost confirmed at booking; packages may reduce the per-test cost.

Why Patients Choose Thamel Clinic for HBV DNA Testing

  • Correct molecular assay — HBV DNA is a DNA virus measured by PCR quantification; we do not confuse it with the HCV RNA test used for hepatitis C.
  • Interpretation, not just numbers — viral load is read together with ALT, HBeAg status and fibrosis findings before any treatment decision.
  • Confidential private care — discreet consultation and protected results in a non-judgmental sexual and liver health clinic.
  • Complete hepatitis pathway — screening, viral load, LFTs, fibrosis assessment and antiviral management under one roof.
  • Long-term monitoring support — structured follow-up schedules so suppression is verified and resistance caught early.
  • Transparent pricing — quoted costs before testing, with package options for full hepatitis workups.
  • Family and partner guidance — advice on household transmission, vaccination and contact testing.

Relevant Specialist Expertise

These clinicians provide care within their scope of practice at our clinic.

Portrait of Dr. Sushil Sitaula, Consultant in Internal Medicine

Dr. Sushil Sitaula

Consultant in Internal Medicine

MBBS
MD — Internal Medicine

Nepal Medical Council Registration No. 6973

Dr. Sushil Sitaula is a Consultant in Internal Medicine with a special interest in sexual health. He holds an MBBS and an MD in Internal Medicine and is registered with the Nepal Medical Council (Registration No. 6973).

Key Expertise

General Internal MedicineSexual HealthSexual HealthGeneral Internal Medicine

Frequently Asked Questions

What does an HBV DNA test measure?

It measures the amount of hepatitis B virus DNA in the blood, reported as international units per millilitre. It reflects active viral replication and is used for staging chronic hepatitis B and monitoring treatment response.

Is HBV DNA the same as an HCV RNA test?

No. Hepatitis B is a DNA virus, so HBV DNA PCR detects its genetic material. Hepatitis C is an RNA virus, so the correct test is HCV RNA. Ordering the wrong molecular assay gives meaningless results.

When is HBV DNA testing needed?

It is needed to decide whether antiviral treatment should start, to establish a baseline before therapy, and to monitor viral suppression every 6 to 12 months during long-term entecavir or tenofovir treatment.

What does an undetectable HBV DNA mean?

It means the virus is suppressed below the assay detection limit — usually because treatment is working or the infection is inactive. It does not mean the virus is cured, and monitoring must continue.

What HBV DNA level means treatment is needed?

Guidelines commonly use thresholds around 2,000 IU/mL combined with elevated ALT and evidence of liver inflammation or fibrosis. The exact decision depends on the full clinical picture, not the viral load alone.

How much does HBV DNA testing cost in Kathmandu?

Molecular viral load testing is priced higher than basic serology because it uses PCR instrumentation. Costs are quoted transparently at booking and are often lower when bundled with LFTs and hepatitis serology.

Can HBV DNA results be very high?

Yes — active hepatitis B can produce loads in the millions of IU/mL, indicating very active replication and higher infectivity. High loads are one reason treatment is started urgently.

Is the test painful?

No. It requires a standard venous blood sample, takes a few minutes, and results are typically available within one to three working days depending on the assay platform.

Should my partner or family be tested?

Yes. Hepatitis B spreads within households, particularly to children. Household contacts should be screened and vaccinated where indicated — your clinician can advise on timing.

Is HBV DNA testing confidential?

Yes. All testing at Thamel Clinic is private and non-judgmental. Results are released only to the patient, with secure handling of samples and reports.

How often should suppressed patients retest DNA?

Most stable patients on effective therapy are monitored every 6 to 12 months with HBV DNA and ALT. Frequency increases if results change or symptoms appear.

What happens if DNA rises while on treatment?

A rising viral load during therapy suggests possible drug resistance or poor adherence. Your doctor may order resistance testing and consider switching to a more potent antiviral — early action prevents liver damage.

Still have questions? Contact us or book an appointment for personalized guidance.

Related Services & Guides

Related Health Guides

Medical Review & Sources

Medically reviewed by: Thamel Clinic Clinical Team (MBBS, MD)

Role: Hepatology and infectious disease clinical reviewers, Thamel Clinic, Kathmandu

Last reviewed: 2026-11-08

Reviewed against current WHO and regional hepatitis B guidance. This is general medical information; a registered clinician must assess each patient before treatment.

View clinic team and credentials

References

  1. Hepatitis B fact sheet — World Health Organization, 2024
  2. Hepatitis B testing and treatment guidance — World Health Organization, 2023
  3. Sexually transmitted infections treatment guidelines — Centers for Disease Control and Prevention, 2021

Medical information is general guidance only and does not replace an individual consultation. Treatment decisions are made after clinical assessment, including allergy and pregnancy review.

Medical Disclaimer

Important information about using this medical website

Educational Purpose Only

The information provided on this website, including all text, graphics, images, and other material, is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

No Doctor-Patient Relationship

Use of this website does not create a doctor-patient relationship. The information provided is not tailored to your specific medical condition or health needs. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Emergency Situations

If you think you may have a medical emergency, call your doctor or emergency services immediately. In Nepal, call 102 for emergency services or go to the nearest hospital emergency room.

Emergency Contact Information:

National Emergency:

102 (Ambulance)

Our Clinic:

+977-9700682800 (WhatsApp available 24/7)

Bir Hospital Emergency:

+977-1-4412400

TU Teaching Hospital:

+977-1-4434320

Timeliness of Information

Medical information changes rapidly. While we strive to provide current and accurate information, we make no guarantees about the completeness, accuracy, reliability, suitability, or availability with respect to the website or the information contained on the website.

Professional Medical Advice Required

Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you have any specific questions about any medical matter, you should consult your doctor or other professional healthcare provider.

Treatment and Diagnosis

Do not use the information on this website to diagnose or treat any health problem or disease. The descriptions of treatments and medications provided are for general informational purposes only and do not constitute medical advice.

Limitation of Liability

In no event shall we be liable for any loss or damage arising from the use of this website or reliance on the information provided herein. This includes, but is not limited to, direct, indirect, incidental, punitive, and consequential damages.

Nepal-Specific Considerations

This website is operated in Nepal and is intended for users in Nepal. The medical information provided may not be applicable to healthcare systems outside Nepal. Always consult with local healthcare providers familiar with Nepal's healthcare system and regulations.

Last Updated: November 20, 2026 |Clinic: Thamel Clinic |Licensed: Registered

WhatsAppBook Now